{"nctId":"NCT00775931","briefTitle":"Allogeneic Transplantation For Severe Osteopetrosis","startDateStruct":{"date":"2008-08"},"conditions":["Severe Osteopetrosis"],"count":7,"armGroups":[{"label":"marrow graft transplant conditioning","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Campath-1H","Radiation: Total Lymphoid Irradiation","Drug: Busulfan","Drug: Fludarabine monophosphate","Procedure: marrow graft transplantation"]},{"label":"cord blood transplant conditioning","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: umbilical cord blood transplantation","Drug: Campath-1H","Drug: Cyclophosphamide","Drug: Busulfan"]}],"interventions":[{"name":"umbilical cord blood transplantation","otherNames":["UCBT"]},{"name":"Campath-1H","otherNames":["Alemtuzumab"]},{"name":"Total Lymphoid Irradiation","otherNames":["TLI"]},{"name":"Cyclophosphamide","otherNames":["Cytoxan"]},{"name":"Busulfan","otherNames":["Busulfex"]},{"name":"Fludarabine monophosphate","otherNames":["Fludara"]},{"name":"marrow graft transplantation","otherNames":["HSCT"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients eligible for transplantation under this protocol will be \\< or = 45 years of age, and will be diagnosed with severe osteopetrosis. This will be defined as having the following manifestations of the disease.\n\n  1. Bones that are uniformly markedly dense based on skeletal survey\n  2. No history that would suggest autosomal dominant inheritance\n  3. Evidence of hematologic changes that are attributed to the underlying disease, including\n* the need for ongoing transfusions, OR\n* the presence of progressive anemia or thrombocytopenia, OR\n* a white blood cell differential with a predominance of immature forms and evidence of extramedullary hematopoiesis, OR\n* persistence of serious infectious complications that are thought to be due to the abnormal architecture of the bone that are resistant to surgical and medical interventions.\n\nExclusion Criteria:\n\n* Patients \\>45 years of age\n* Evidence of hepatic failure\n* Pulmonary dysfunction sufficient to significantly increase the risk of transplant.\n* Renal dysfunction with glomerular filtration rate (GFR) \\<30% of predicted.\n* Cardiac compromise sufficient to substantially increase the risk of transplantation\n* Severe, stable neurologic impairment.\n* Human immunodeficiency virus (HIV) positivity.\n* Pregnant or lactating females","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Day","maximumAge":"45 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients Who Achieved Donor Cell Engraftment","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Transplant Related Mortality at 100 Days","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Transplant Related Toxicity","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Grade II - IV Acute Graft-versus-host Disease","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":6},"commonTop":["Requires Intubation, NOS","Pericardial Effusion","Pneumonia","Bacterial Infection, Blood","Fungal Infection, Respiratory"]}}}